Current drug targets最新文献

筛选
英文 中文
Role of Artificial Intelligence in Nanomedicine and Organ-specific Therapy: An Updated Review. 人工智能在纳米医学和器官特异性治疗中的作用:最新综述。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-22 DOI: 10.2174/0113894501394785250715165404
Kuldeep Rajpoot
{"title":"Role of Artificial Intelligence in Nanomedicine and Organ-specific Therapy: An Updated Review.","authors":"Kuldeep Rajpoot","doi":"10.2174/0113894501394785250715165404","DOIUrl":"https://doi.org/10.2174/0113894501394785250715165404","url":null,"abstract":"<p><strong>Background: </strong>In organ-specific therapy, artificial intelligence (AI) is primarily used to improve surgical planning through image analysis, predict post-transplant outcomes, personalize treatment plans based on patient data, optimize organ allocation logistics, and donor-recipient precision mapping for organs to improve transplants. Furthermore, all these applications ultimately lead to better patient outcomes and enhanced organ therapy.</p><p><strong>Objective: </strong>This review aims to examine the revolutionary effects of AI in some key healthcare fields, such as nanomedicine, cancer treatment, clinical applications, and organ-specific delivery.</p><p><strong>Methods: </strong>This review article discusses in detail the role of AI in nanomedicine, cancer therapy, clinical applications, organ-specific delivery (e.g., cardiovascular, gastroenterology, kidney, liver, lung, ophthalmology, skin, etc.), diagnosis, and radiotherapy. In addition, it also discusses limitations and challenges of AI in healthcare.</p><p><strong>Results: </strong>AI-based clinical translation has potential but faces challenges like artifact vulnerability, ethical and legal considerations, and security measures. Restrictive data-use policies may hinder accurate analysis. Regulations and collaboration with data-sharing mechanisms could overcome barriers.</p><p><strong>Conclusion: </strong>AI is being utilized in organ-specific therapy to enhance donor-recipient matching, surgical planning, post-transplant outcomes prediction, and personalized treatment plans by analyzing patient data.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative Strategies and Advances in Drug Delivery Systems to Address Poor Solubility: A Comprehensive Review. 解决溶解度差的药物输送系统的创新策略和进展:全面回顾。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-21 DOI: 10.2174/0113894501375776250713110838
Hossamaldeen Bakrey, Abdulkadir Abdu, Riya Shivgotra, Bindu Soni, Manya Sharma, Alaa Bakrey, Subheet Kumar Jain
{"title":"Innovative Strategies and Advances in Drug Delivery Systems to Address Poor Solubility: A Comprehensive Review.","authors":"Hossamaldeen Bakrey, Abdulkadir Abdu, Riya Shivgotra, Bindu Soni, Manya Sharma, Alaa Bakrey, Subheet Kumar Jain","doi":"10.2174/0113894501375776250713110838","DOIUrl":"https://doi.org/10.2174/0113894501375776250713110838","url":null,"abstract":"<p><p>Poor solubility remains a significant obstacle in drug administration, adversely affecting the bioavailability and therapeutic efficacy of many drugs. It is also recognized as a primary factor contributing to issues with bioavailability, such as poor, inconsistent, limited, and highly variable bioavailability of marketed products. It is estimated that 40% of marketed drugs face bioavailability challenges primarily due to poor water solubility, and about 90% of pharmacological compounds exhibit poor water solubility in their early development stages. Addressing this issue is crucial for improving drug performance, efficacy, and patient outcomes. This review provides an overview of the challenges associated with poorly soluble drugs, including low bioavailability, limited dissolution rates, inconsistent absorption, decreased patient compliance, formulation difficulties, and associated costs and time constraints. Numerous strategies have been now investigated to tackle the issue of poor solubility. This review offers an updated overview of commonly used macro and nano drug delivery systems, including micelles, nanoemulsions, dendrimers, liposomes, lipid-based delivery systems, microemulsions, cosolvents, polymeric micelle preparation, drug nanocrystals, solid dispersion methods, crystal engineering techniques, and microneedle- based systems. Additionally, the review examines advanced techniques like cyclodextrin- based delivery systems, co-solvency and co-crystallization approaches, polymeric micelles, spray drying, co-precipitation, and amorphous solid dispersion. The role of computational modeling and formulation prediction is also addressed. Recent advancements in protein-based approaches, 3D printing, mesoporous silica nanoparticles, supramolecular delivery systems, magnetic nanoparticles, nanostructured lipid carriers, and lipid-based nanoparticles are highlighted as novel solutions for enhancing the solubility of poorly soluble drugs. The review concludes with predictions for the future, emphasizing the potential for further innovation in drug delivery methods to overcome the challenges associated with poorly soluble drugs.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modern Solutions to UTIs: The Role of Nanotechnology and Herbal Treatments. 尿路感染的现代解决方案:纳米技术和草药治疗的作用。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-21 DOI: 10.2174/0113894501371882250713174322
Ashutosh Kumar, Amit Kumar, Md Moidul Islam, Ranadeep Borgohain, Sarjana Raikwar
{"title":"Modern Solutions to UTIs: The Role of Nanotechnology and Herbal Treatments.","authors":"Ashutosh Kumar, Amit Kumar, Md Moidul Islam, Ranadeep Borgohain, Sarjana Raikwar","doi":"10.2174/0113894501371882250713174322","DOIUrl":"https://doi.org/10.2174/0113894501371882250713174322","url":null,"abstract":"<p><strong>Introduction: </strong>Urinary tract infections (UTIs) range from mild to severe cases, commonly caused by uropathogenic Escherichia coli (E. coli). The growing concern about antibiotic resistance demands alternative treatment strategies. Nanotechnology, particularly nanocarriers, presents a promising solution by enhancing drug delivery, antibacterial activity, and targeted therapy. This review focuses on the emerging role of combining herbal remedies with nanotechnology for more effective and personalized management of UTIs, aiming to overcome the limitations of conventional antibiotic therapies.</p><p><strong>Methods: </strong>The review involved an extensive search of scientific databases and relevant literature, including studies published to date from PubMed, Science Direct, and Google Scholar. Urinary tract infections (UTI), antibiotic resistance, nanotechnology, drug delivery, targeted drug delivery, and herbal drugs were among the search phrases used.</p><p><strong>Result: </strong>According to studies, combining herbal extracts such as neem and turmeric with nanotechnology significantly enhances antimicrobial activity against UTI pathogens. These nanoformulations show enhanced bacterial inhibition, reduced inflammation, and increased therapeutic precision with minimal side effects.</p><p><strong>Discussion: </strong>The synergistic use of herbal remedies and nanocarriers offers a novel approach to managing UTIs. Nanotechnology not only enhances drug delivery but also improves diagnostic accuracy through fluorescence markers and biomolecule tagging. This strategy effectively addresses growing antibiotic resistance and supports the development of personalized treatments. The combination of natural bioactives and advanced delivery systems offers a safer, more effective alternative to conventional antibiotics in treating UTIs.</p><p><strong>Conclusion: </strong>The integration of nanotechnology and herbal therapies revolutionizes UTI management through precision medicine. This approach enhances treatment efficacy, diagnostic accuracy, and patient outcomes, offering a personalized solution to combat antibiotic resistance and urinary tract abnormalities with improved targeting and minimal side effects.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Drug Monitoring: A New Hope for Individualised Treatment with Venetoclax. 治疗药物监测:Venetoclax个体化治疗的新希望。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-16 DOI: 10.2174/0113894501376271250710221018
Yue Tang, Shuojiao Li, Peng Rao, Wenxian Yu, Xuanpeng Jiang, Jiatao Liu
{"title":"Therapeutic Drug Monitoring: A New Hope for Individualised Treatment with Venetoclax.","authors":"Yue Tang, Shuojiao Li, Peng Rao, Wenxian Yu, Xuanpeng Jiang, Jiatao Liu","doi":"10.2174/0113894501376271250710221018","DOIUrl":"https://doi.org/10.2174/0113894501376271250710221018","url":null,"abstract":"<p><p>B-cell lymphoma-2 (BCL-2) plays a key role in regulating apoptosis. Venetoclax (VEN), a BCL-2 inhibitor, has been approved for the treatment of a variety of haematologic malignancies. VEN is primarily metabolized by CYP3A, and a variety of factors (such as CYP3A inhibitors, as well as food and hepatic functions) have been reported to significantly influence the metabolic process. There is significant interindividual variability in VEN plasma concentrations, and studies have shown that its exposure levels are correlated with efficacy, although the relationship with adverse effects remains controversial. The value of applying of therapeutic drug monitoring (TDM) in individualized VEN therapy has been confirmed by some studies, but the optimal therapeutic window for different malignancies is still unclear. This review summarizes the pharmacokinetic characteristics, along with the factors influencing VEN pharmacokinetics, drug-drug interactions, and advancements in TDM research on VEN, aiming to provide a theoretical basis for TDM-guided individualized therapy.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases. 跨越边界:杂环化合物在癌症和传染病管理中的多种功能综述。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-09 DOI: 10.2174/0113894501372336250703114127
Pranay Wal, Ankita Wal, Talha Jawaid, Paramita Ganguly, Binit Patel, Pankaj Nainwal, Mohd Qasid Lari, Ajay Kumar, Dileep Kumar
{"title":"Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases.","authors":"Pranay Wal, Ankita Wal, Talha Jawaid, Paramita Ganguly, Binit Patel, Pankaj Nainwal, Mohd Qasid Lari, Ajay Kumar, Dileep Kumar","doi":"10.2174/0113894501372336250703114127","DOIUrl":"https://doi.org/10.2174/0113894501372336250703114127","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Heterocyclic molecules, a mainstay of contemporary medicinal chemistry, are essential in developing antibacterial and anticancer treatments. Their distinct structural features-one or more heteroatoms within the ring-allow for a wide range of biological activities. With a focus on their modes of action and insights into the structure-activity relationship (SAR), this study examines the therapeutic uses of heterocyclic compounds in antibacterial, antifungal, antiviral, and anticancer treatments.</p><p><strong>Methods: </strong>The review uses search engines like PubMed and Google Scholar, with a preference for English as the major language, to gather and analyse recent research on the antibacterial and anticancer applications of diverse heterocyclic compounds.</p><p><strong>Results: </strong>It has been discovered that heterocyclic chemicals are useful in blocking microbial enzymes, including DNA gyrase and the machinery involved in protein synthesis. Heterocyclic compounds such as benzimidazoles, quinolines, and acridines have demonstrated noteworthy efficacy in cancer therapy through their targeting of tubulin inhibition, DNA intercalation, and signalling pathways like PI3K/Akt/mTOR and MAPK. The pharmacological characteristics of these compounds were improved by the addition of electron-withdrawing groups, halogenation, and heteroatom replacements, according to SAR investigations.</p><p><strong>Conclusion: </strong>Heterocyclic compounds have great promise for antibacterial and anticancer treatments. They are crucial in drug development because of their structural flexibility, which enables the targeted suppression of vital biological processes. The effectiveness of heterocyclic compounds will continue to be improved by ongoing advancements in drug design and SAR optimization, opening new possibilities for the creation of more potent and selective medicinal treatments.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer. GSTP1, PRDX2和NFE2L2:原发性乳腺癌的潜在标志物
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-04 DOI: 10.2174/0113894501393175250627013915
Syeda Abiha Zehra Jaffari, Fatima Haider, Nida Syed, Amber Ilyas, Farha Idrees, Alex von Kriegsheim, Roopesh Krishnankutty, Syeda Nuzhat Nawab, Zehra Hashim
{"title":"GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer.","authors":"Syeda Abiha Zehra Jaffari, Fatima Haider, Nida Syed, Amber Ilyas, Farha Idrees, Alex von Kriegsheim, Roopesh Krishnankutty, Syeda Nuzhat Nawab, Zehra Hashim","doi":"10.2174/0113894501393175250627013915","DOIUrl":"https://doi.org/10.2174/0113894501393175250627013915","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early- stage markers for breast cancer.</p><p><strong>Methods: </strong>Normal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) with patient consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry.</p><p><strong>Results: </strong>The protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues.</p><p><strong>Discussion: </strong>Our study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage.</p><p><strong>Conclusion: </strong>It can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early- stage markers for diagnosis and potential therapeutic targets for breast cancer.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matrix Metalloproteinase-9: A Key Diagnostic Biomarker in Cancer Progression. 基质金属蛋白酶-9:癌症进展的关键诊断生物标志物。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-04 DOI: 10.2174/0113894501371763250628092643
Arpita Srivastava, Jatin Gupta, Shivani Singhal, Hardeep Tulli, Neetu Mishra, Neha Atale, Buddhi Prakash Jain, Christophe Grosset, Bhawna Saxena, Vibha Rani
{"title":"Matrix Metalloproteinase-9: A Key Diagnostic Biomarker in Cancer Progression.","authors":"Arpita Srivastava, Jatin Gupta, Shivani Singhal, Hardeep Tulli, Neetu Mishra, Neha Atale, Buddhi Prakash Jain, Christophe Grosset, Bhawna Saxena, Vibha Rani","doi":"10.2174/0113894501371763250628092643","DOIUrl":"https://doi.org/10.2174/0113894501371763250628092643","url":null,"abstract":"<p><p>Matrix metalloproteinase-9, also known as MMP-9, gelatinase B, or 92 kDa type IV collagenase, is an enzyme that belongs to the matrix metalloproteinase (MMP) family. It is involved in the remodeling of the extracellular matrix in various physiological and pathological processes. MMPs are expressed in low, tightly regulated concentrations; their overexpression or dysregulation can lead to diseases, including cancer. MMP-9 is increasingly recognized as a significant drug target in cancer therapy due to its involvement in tumorigenesis, including processes like cell migration, angiogenesis, and pro-apoptotic and anti-apoptotic activities. Despite MMP-9's significance as a cancer target, developing effective inhibitors remains challenging due to MMP structural similarities. Utilizing MMP-9 as a cancer biomarker could advance cancer diagnosis, prognosis, disease monitoring, recurrence prediction, and other procedures. Biosensors are emerging as pivotal tools in cancer diagnosis and treatment, leveraging their ability to detect specific biomarkers associated with various cancers. Recent advancements have led to the development of both cleavage-based and non-cleavage-based biosensors that enable rapid and sensitive analysis at clinically relevant concentrations of biomarkers while allowing specificity and low detection limits, enhancing point-of-care diagnostics. The cleavage-based biosensors leverage the enzymatic activity of MMP-9, utilizing substrates that are specifically cleaved by MMP-9, while the non-cleavage- based biosensors employ affinity methods, such as antibodies and aptamers for detection. The present review aims to evaluate the role of MMP-9 as a significant biomarker in cancer and its detection through innovative biosensor technologies, while exploring its involvement in various cancer- related processes. This review discusses the significance of MMP-9 in cancer progression, highlighting clinical trials that assess MMP-9 inhibitors as potential therapeutic agents to halt metastatic spread. Furthermore, MMP-9 is detected via biosensors, and insights into the translational potential of MMP-9 both as a biomarker for early cancer detection and a viable target for therapeutic intervention are provided, ultimately contributing to improved patient outcomes in oncology.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RMNet: An RNA m6A Cross-species Methylation Detection Method for Nanopore Sequencing. RMNet:用于纳米孔测序的RNA m6A跨物种甲基化检测方法。
IF 3 4区 医学
Current drug targets Pub Date : 2025-07-04 DOI: 10.2174/0113894501405283250627072052
Qingwen Li, Chen Sun, Daqian Wang, Jizhong Lou
{"title":"RMNet: An RNA m6A Cross-species Methylation Detection Method for Nanopore Sequencing.","authors":"Qingwen Li, Chen Sun, Daqian Wang, Jizhong Lou","doi":"10.2174/0113894501405283250627072052","DOIUrl":"https://doi.org/10.2174/0113894501405283250627072052","url":null,"abstract":"<p><strong>Introduction: </strong>N6-methyladenosine (m6A) is the most prevalent RNA modification in eukaryotic cells, influencing RNA lifecycle processes. Existing m6A detection methods, such as wet-lab techniques and statistical approaches, are time-consuming, labor-intensive, or require control samples, while machine learning models often lack cross-species applicability. This study aims to develop RMNet, a robust cross-species m6A detection method using nanopore sequencing.</p><p><strong>Methods: </strong>RMNet employs Conformer and RNN architectures, integrating signal and alignment features from nanopore sequencing data. Contrastive learning enhances differentiation between m6A and non-m6A sites. The model was trained and tested on datasets from synthesized RNA, Arabidopsis, and human samples, using a single set of model weights.</p><p><strong>Results: </strong>RMNet achieved state-of-the-art performance with accuracies of 99.7% for synthesized RNA, 78.8% for Arabidopsis, and 88.9% for human datasets. It outperformed existing methods (m6Anet, DENA, and RedNano) across six metrics, including AUC and AUPR, demonstrating robust cross-species generalization.</p><p><strong>Discussion: </strong>RMNet's ability to detect m6A sites across diverse species with a single model addresses limitations of species-specific models. Its high sensitivity and feature representation enable applications in cancer research, neurodevelopmental studies, and plant biology. Limita-tions include higher error rates in human datasets for thymine-rich k-mers, likely due to complex secondary structures.</p><p><strong>Conclusion: </strong>RMNet provides an efficient, powerful tool for cross-species m6A detection, advancing epitranscriptomics research with potential applications in precision medicine and agri-cultural science.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipidomics in Breast Cancer: Decoding Metabolic Reprogramming and Unlocking Therapeutic Opportunities. 乳腺癌的脂质组学:解码代谢重编程和释放治疗机会。
IF 3 4区 医学
Current drug targets Pub Date : 2025-06-24 DOI: 10.2174/0113894501387287250611095023
Harshita Singhai, Sunny Rathee, Umesh K Patil
{"title":"Lipidomics in Breast Cancer: Decoding Metabolic Reprogramming and Unlocking Therapeutic Opportunities.","authors":"Harshita Singhai, Sunny Rathee, Umesh K Patil","doi":"10.2174/0113894501387287250611095023","DOIUrl":"https://doi.org/10.2174/0113894501387287250611095023","url":null,"abstract":"<p><p>Lipidomics, a cutting-edge branch of metabolomics, provides a comprehensive understanding of the lipidome and its alterations in cellular and systemic processes. In breast cancer, a highly heterogeneous disease, lipidomics has emerged as a pivotal tool for exploring metabolic reprogramming, tumor progression, and therapeutic resistance. This review highlights the intricate relationship between lipid metabolism and breast cancer, with a focus on subtype-specific lipid dependencies, oxidative stress, and ferroptosis. Technological advancements, such as mass spectrometry and chromatography, have enabled precise profiling of lipid alterations, revealing distinct lipid signatures across breast cancer subtypes. Key enzymes like acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), along with lipid regulators like PPARγ, have been identified as central players in lipid-driven tumorigenesis. Lipidomic studies offer the potential for biomarker discovery and the development of lipid-targeted therapies. Despite challenges in standardization and integration with other omics approaches, lipidomics is poised to revolutionize breast cancer diagnostics and therapeutics, providing novel insights into the metabolic underpinnings of this complex disease.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of PGE2 in Age-related Diseases. PGE2在年龄相关疾病中的作用
IF 3 4区 医学
Current drug targets Pub Date : 2025-06-24 DOI: 10.2174/0113894501383329250616070727
Jun Guan, Chao Chen, Shanshan Wu, Haihong Zhu
{"title":"The Role of PGE2 in Age-related Diseases.","authors":"Jun Guan, Chao Chen, Shanshan Wu, Haihong Zhu","doi":"10.2174/0113894501383329250616070727","DOIUrl":"https://doi.org/10.2174/0113894501383329250616070727","url":null,"abstract":"<p><p>In the past several years, human life expectancy has increased dramatically, and the global aging process is accelerating at an unprecedented rate. Impaired organ functions and systemic inflammation increase the risk of aging-related diseases. It seriously affects the quality of life in older adults and places a heavy burden on the global economy and public health. Inflammation is the cornerstone of many age-related diseases, and among various inflammatory mediators, Prostaglandin E2 (PGE2) has emerged as a key player. For example, PGE2 could participate in the progression of Alzheimer's disease (AD) by modulating neuroinflammation. Plasma PGE2 is regarded as a potential and specific diagnostic biomarker, and higher initial PGE2 levels are positively correlated with longer survival in AD. PGE2 also mediates bone and muscle metabolism to affect age-related musculoskeletal diseases, including sarcopenia, osteoporosis, and osteoarthritis. It activates the EP4 receptor on sensory nerves to inhibit sympathetic nerve activity and modulate bone formation. Moreover, the PGE2/EP4 axis positively regulates muscle mass and strength. In diabetes, increased Cox-2 and m-PGES2 promote PGE2 production. The activated PGE2/EP3 axis exacerbates the progression of type 2 diabetes (T2D) by impairing glucose metabolism and accelerating β-cell senescence. Therefore, the role of PGE2 in age-related diseases deserves greater attention. Its involvement is driven by the dysregulation of its biosynthesis, metabolism, and receptor- mediated signaling. Regulating the concentration of PGE2 or modulating receptor activity represents a promising therapeutic strategy for managing age-related diseases.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信